Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated <i>Plasmodium falciparum</i> malaria in Gia Lai province, Vietnam from 2022 to 2023
Although Pyramax® remains efficacious in treating P. falciparum, the lower pyronaridine concentrations in patients who had recrudescent malaria are worrisome and suggest that reduced pyronaridine exposure may be responsible for the Pyramax® treatment failures.
Authors
- Chau Van Khanh (ORCID: https://orcid.org/0009-0006-9787-2316)
- Andrew G. Letizia
- Nguyễn Ngọc San
- Nguyễn Thị Minh Trinh
- Marina Chavchich (ORCID: https://orcid.org/0000-0002-8142-8468)
- Geoffrey W. Birrell (ORCID: https://orcid.org/0000-0002-6593-1514)
- Kimberly A. Edgel
- Michael D. Edstein (ORCID: https://orcid.org/0000-0002-6975-1799)
- Huy C Nguyen (ORCID: https://orcid.org/0009-0005-2623-6956)
- Nicholas J. Martin (ORCID: https://orcid.org/0000-0002-2030-8702)
- Nguyễn Văn Thành (ORCID: https://orcid.org/0000-0001-6851-1593)
- Nguyễn Quốc Cường
- Huynh Hong Quang
Institutions
- Hanoi Medical University (VN)
- United States Naval Medical Research Unit SOUTH (PE)
- Department of Defence (AU)
- Vietnam Military Medical University (VN)
- Quy Nhon University (VN)
- National Institute of Malariology, Parasitology and Entomology (VN)
- 108 Military Central Hospital (VN)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/jac/dkaf234
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Armed Forces Health Surveillance Branch